Provided by Tiger Trade Technology Pte. Ltd.

Avidity Biosciences, Inc.

71.87
-0.1000-0.14%
Post-market: 71.870.00000.00%18:14 EST
Volume:2.04M
Turnover:146.52M
Market Cap:10.83B
PE:-17.17
High:72.02
Open:71.91
Low:71.84
Close:71.97
52wk High:72.02
52wk Low:21.51
Shares:150.68M
Float Shares:113.00M
Volume Ratio:0.98
T/O Rate:1.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1851
EPS(LYR):-2.8885
ROE:-32.44%
ROA:-20.28%
PB:5.74
PE(LYR):-24.88

Loading ...

PRESS DIGEST- Financial Times - October 27

Reuters
·
Oct 27

BRIEF-Avidity Biosciences Says Spinco To Be Led By Kathleen Gallagher As Ceo

Reuters
·
Oct 27

Avidity Biosciences Enters Into Agreement to Be Acquired by Novartis Ag

THOMSON REUTERS
·
Oct 27

Avidity Biosciences Inc - Spinco to Be Led by Kathleen Gallagher as CEO

THOMSON REUTERS
·
Oct 27

Novartis to acquire Avidity Biosciences for $12 billion

Reuters
·
Oct 27

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

GlobeNewswire
·
Oct 27

Novartis Set to Announce $10Bn Plus Avidity Biosciences Purchase-FT

THOMSON REUTERS
·
Oct 27

Novartis close to deal to buy Avidity for over $70 per share, Bloomberg says

TIPRANKS
·
Oct 26

BRIEF-Novartis Said To Near $70-Per-Share-Plus Deal For Avidity-Bloomberg News

Reuters
·
Oct 26

Novartis Said to Near $70-per-Share-Plus Deal for Avidity-Bloomberg News

THOMSON REUTERS
·
Oct 26

Avidity Biosciences Chief Medical Officer Steven George Hughes Reports Disposal of Common Shares

Reuters
·
Oct 25

CSPC PHARMA (01093): SYH2061 Injection (Dual-Chain Small Interfering RNA Drug) Approved for Clinical Trials in China

Stock News
·
Oct 24

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

GlobeNewswire
·
Oct 20

Avidity Biosciences Inc. Chief Human Resources Officer Teresa McCarthy Reports Disposal of Common Shares

Reuters
·
Oct 18

Avidity Biosciences Delays Biologics License Application

TIPRANKS
·
Oct 14

Avidity Biosciences Showcases Advancements in RNA Therapeutics and Progress Toward Commercializing Rare Neuromuscular Disease Treatments

Reuters
·
Oct 14

BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv

Reuters
·
Oct 14

BUZZ-Avidity rises on plans to submit muscle wasting drug application to US FDA

Reuters
·
Oct 13

BRIEF-Avidity Biosciences Announces Positive Pre-BLA Meeting With US FDA For del-zota In DMD44

Reuters
·
Oct 13

Avidity Biosciences Announces Positive Pre-Bla Meeting With U.S. FDA for Del-Zota in Dmd44 With a Submission Planned for Q1 2026

THOMSON REUTERS
·
Oct 13